OPTIMISING SYNCHROTRON MICROBEAM RADIATION THERAPY FOR CANCER TREATMENT
Grant number: 606614 | Funding period: 2010 - 2012
Over 50% of cancer patients receive radiotherapy (RT). Tumour control using RT is limited by adverse normal tissue reactions. Unlike conventional RT machines, the Australian synchrotron has the capability to deliver strong radiation in very thin slices, termed microbeam RT (MRT). Tumour control has been obtained in animal models with a remarkable sparing of normal tissue using MRT. We will optimize MRT as a crucial step towards a potentially revolutionary cancer treatment.
Related publications (5)
An evaluation of novel real-time technology as a tool for measurement of radiobiological and radiation-induced bystander effects
Mohammad Johari Ibahim, Jeffrey C Crosbie, Premila Paiva, Yuqing Yang, Marina Zaitseva, Peter AW Rogers
The xCELLigence real-time cell impedance system uses a non-invasive and label-free method to create a cell index that is a composi..
In Vitro Study of Genes and Molecular Pathways Differentially Regulated by Synchrotron Microbeam Radiotherapy
Yuqing Yang, Jeffrey C Crosbie, Premila Paiva, Mohammad Ibahim, Andrew Stevenson, Peter AW Rogers
The aim of this study was to identify genes and molecular pathways differentially regulated by synchrotron-generated microbeam rad..
An Evaluation of Dose Equivalence between Synchrotron Microbeam Radiation Therapy and Conventional Broadbeam Radiation Using Clonogenic and Cell Impedance Assays
Mohammad Johari Ibahim, Jeffrey C Crosbie, Yuqing Yang, Marina Zaitseva, Andrew W Stevenson, Peter AW Rogers, Premila Paiva
BACKGROUND: High-dose synchrotron microbeam radiation therapy (MRT) has shown the potential to deliver improved outcomes over conv..
Reference dosimetry at the Australian Synchrotron's imaging and medical beamline using free-air ionization chamber measurements and theoretical predictions of air kerma rate and half value layer
Jeffrey C Crosbie, Peter AW Rogers, Andrew W Stevenson, Christopher J Hall, Jessica E Lye, Terese Nordstrom, Stewart M Midgley, Robert A Lewis
PURPOSE: Novel, preclinical radiotherapy modalities are being developed at synchrotrons around the world, most notably stereotacti..
Genome-Wide Transcription Responses to Synchrotron Microbeam Radiotherapy
Carl N Sprung, Yuqing Yang, Helen B Forrester, Jason Li, Marina Zaitseva, Leonie Cann, Tina Restall, Robin L Anderson, Jeffrey C Crosbie, Peter AW Rogers
The majority of cancer patients achieve benefit from radiotherapy. A significant limitation of radiotherapy is its relatively low ..